Skip to main content

Table 1 T cell-depleted and unmanipulated haploidentical stem cell transplantation

From: Current status of haploidentical stem cell transplantation for leukemia

Centers (year) Disease No. of pts Conditioning GVHD prophylaxis Cell dose 106/kg   TCD methods Graft failure Acute GVHD Chronic GVHD TRM Relapse DFS
      CD34 CD3        
T-cell depleted
Perugia, Italy
1994[16]
AML/ALL/CML 36 TBI/TT/CY/ATG Extensive TCD 10.8 0.22 Lectin-based+E-rosette 1/17 1/16 0/9 9/17 2/17 6/17
USC, USA
1997[12]
AML/ALL 72 TBI/VP16/Ara-C/CY/ATG Partial TCD
CSP, MP, ATG
1.36 0.075 Ex vivo TCD with T10B9 2% 16% 35% 65.3% 32% 2-year OS
55% for SR
27% for HR
Perugia, Italy
1998[17]
AML
ALL
44 TBI/TT/F/ATG Extensive TCD 10.5 0.02 Ex vivo CD34 selection 5% 0 0 40% 13%
63%
36%
17%
Boston, USA
1999[40]
AML/ALL/NHL/others 12 TBI/Ara-c/CY CTLA4-Ig, CSP+MTX 2.2 28 CTLA4-Ig, 1/11 3/11 1/11 7/12 1/12 5/12
Multicenter, Japan
2000[61]
Leukemia/others 135 TBI-based CSP/Tac/MTX/Steroids 3.2
5.5
4.9
0.06(M)
0.09(P)
0.01(M+P)
Ex vivo CD34+ selection 13% II~IV
21%
35% 47% 22%for SR
79%for HR
5-year
39% for SR
5% for HR
Tuebingen, Germany
2004[22]
AML/ALL/others 63 TBI or Bu-based with F/TT/ATG/Cy Extensive TCD 19.5 0.011 Ex vivo CD34/CD133 selection 17% II 7% 13% 28% 30% 3-year
48% (ALL/NHL)
USC, USA
2004[13]
AML/ALL 201 TBI/VP16/Ara-C/Cy/ATG Partial TCD
CSP, MP, ATG
1.9 0.05 Ex vivo TCD with T10B9/OKT3 2% 13% 15% 51% 31% 5-year 18%
Multicenter, Canada,
2004[62]
AML 11 Mel/TT/F/ATG TCD 13.7 0.005 Ex vivo CD34 selection 0% 0% NA 55% 37% 9-month 9%
Perugia, Italy
2005[18, 21]
AML/ALL/CML 175 TBI/TT/F/ATG Extensive TCD 12.8 0.01 Ex vivo CD34 selection 6% II~IV 8% 4% 36.5% 24% for AML
27% for ALL
5-year
47% in CR
4% in rel
Tuebingen, Germany
2007[25]
HM/AA 38 F/TT/Mel/OKT3 TCD 16 0.049 CD3/CD19 negative selection 17% II~IV 27%    2.6% 70% for SR
20% for HR
Multicenter, Germany
2008[24]
HM 29 F/TT/Mel/OKT3 TCD 7.6 0.044 CD3/CD19 negative selection 0% II~IV 48% 3/29 8/29 41% 1-year 35%
Non-T-cell depleted
Jone-Hopkins University
2004[37]
Leukemia/MDS 56 F/CY/TBI(2 Gy) Tac/MMF/CY NA NA Not done 17% 66% NR 9%(d100) NA 1-year 38%
Beijing, China
2006[11]
ALL/AML/CML/MDS 171 Bu/Ara-C/CY/Me-CCNU/ATG CSP/MMF/MTX short 1.8 220 Not done 0 55% 47% 2-year
19% for SR
31% for HR
12% for SR
39% for HR
2-year
68% for SR
42% for HR
Japan, 2006[39] Leukemia/lymphoma 26 F/Bu/ATG Tac/MP 6.55 254 In vitro TCD with ATG 4% 19% 25% 15% (d100)   3-year 61%
Duke University, USA
2007[38]
Leukemia/MDS/MPD 49 F/CY/Alemtuzumab MMF ± CSP
Partial TCD
13.5 460 In vivo ± ex vivo TCD/Alemtuzumab 14% 16% 14% 31% 49% 1-year 43%
  1. *AML = acute myeloid leukemia; ALL = acute lymphoid leukemia; Ara-C = cytarabine; ATG = anti-thymocyte globulin; BU = busulfan; CML = chronic myeloid leukmemia; CR = complete remission; CSP = cyclosporine A; CY = cyclophosphamide; DFS = disease free survival; F = fludarabine; GVHD = graft versus host disease; HM = hematologic malignancies; HR = high risk; MDS = myelodysplastic syndrome; Mel = melphalan; MMF = mycophenolate mofetil; MP = methylprednisolone; MTX = methotrexate; NA = not available; NHL = non-Hodgkin lymphoma; OS = overall survival; pts = patients; rel = relapse; SR = standard risk; Tac = tacrolimus; TBI = total body irradiation; TCD = T-cell depletion; TRM = transplant related motality; TT = thiotepa.